Patients with Brugada syndrome had reduced cyclic AMP and norepinephrine concentrations in endomyocardial biopsies compared to controls.
Case-Control (n=13)
Does the biochemical profile of sympathoadrenergic signaling pathways differ in endomyocardial biopsies of patients with Brugada syndrome compared to controls?
Patients with Brugada syndrome exhibit reduced myocardial norepinephrine and cAMP concentrations, providing biochemical evidence of adrenergic dysfunction that may contribute to arrhythmogenesis.
BACKGROUND: In patients with Brugada syndrome (BrS), life-threatening ventricular tachyarrhythmias predominantly occur during vagal stimulation at rest or during sleep. Previous imaging studies displayed an impaired autonomic function in BrS patients. However, it remains unclear whether these alterations primarily stem from a reduction of synaptic release of norepinephrine (NE) or an enhanced presynaptic reuptake. Both conditions could lead to reduced NE concentrations in the synaptic cleft. Therefore, we analyzed key components of the sympathoadrenergic signaling pathways in patients with BrS. METHODS AND RESULTS: Endomyocardial biopsies were obtained from eight BrS patients (seven male; age 49 ± 15 years) and five controls (three male; age 43 ± 13 years; P = ns). The concentrations of NE, epinephrine (Epi), NE transport (NET) carrier protein, cyclic adenosine 5'monophosphate (cyclic adenosine monophosphate cAMP), inhibitory G-proteins (G(i1,2) α), troponin-I (TNI), and phosphorylated TNI were analyzed. Levels of NET, G(i1,2) α, TNI, Epi, and phosphorylated TNI were comparable between the groups. Compared to controls, patients with BrS showed reduced cAMP and NE concentrations. CONCLUSIONS: The current findings expand the concept of adrenergic dysfunction in BrS: the reduction of NE in BrS could lead to an impaired stimulation of β-adrenoceptors resulting in a reduction of cAMP and alterations of the subsequent signaling pathway with potential implication for arrhythmogenesis.
Paul et al. (Mon,) conducted a case-control in Brugada syndrome (n=13). Brugada syndrome vs. Controls was evaluated on Concentrations of key components of the sympathoadrenergic signaling pathways (NE, Epi, NET, cAMP, Gi1,2 α, TNI, and phosphorylated TNI). Patients with Brugada syndrome had reduced cyclic AMP and norepinephrine concentrations in endomyocardial biopsies compared to controls.